Go to any support group meeting and you are almost sure to hear someone, usually a new member of the group, ask about what they might do to lower their risk of having their prostate cancer progress or even lower their risk of dying from the prostate cancer. Among the common answer to this question [...]
So, you are a hero and have decided to participate in a clinical trial. We all are deeply in your debt, so I want to start out and extend to you a very big thank you. Making that decision to participate in a clinical trial isn’t an easy decision for anyone. Participating in a trial [...]
Today the vast majority of us have access to a computer as well as the Internet. Thanks to powerful search engines we all have easy access to the world, including to an explosion of information about our health. The fact that you are reading this blog is the best example I could offer. However, in [...]
Malecare and the University of Minnesota are well on the way to making the Restore study, the largest and most comprehensive survey of gay and bisexual men with prostate cancer ever conducted. The Restore study is funded by the National Cancer Institute at NIH and is now recruiting men to complete their survey. You can [...]
For men with metastatic prostate cancer, understanding ones prostate specific antigen (PSA) kinetics is important. Despite the issues we hear surrounding the PSA, it is still the best measure you have in aiding you in the assessing your possible outcome prognosis. PSA kinetics also are a potential surrogate marker for clinical trial results. In most [...]
Teva Pharmaceutical Industries has received approval and launched, in the United States, a generic version of the Avodart (dutasteride) capsules at the 0.5 mg dose. Avodart, 5-alpha reductase inhibitor, is FDA approved for the treatment of men with benign prostate hyperplasia (an enlarged prostate gland), however, although not approved; men often use it as a [...]
There are many trials and tribulations facing new drug approvals for men with prostate cancer. This is particularly true for men the drugs that are designed to fight metastatic castration-resistant prostate cancer (mCRPC) because of the many new treatments, all with life extending ability, that we now have available to use. The good news is [...]
I stumbled upon a fascinating piece of research from Iceland that looked at the role of Circadian Disruption in Prostate Cancer Development. Knowing my own very poor sleeping patterns and having heard many other men with advanced prostate cancer complaining about very similar experiences it peaked my interest. The researchers pointed out that there have [...]
It is commonly known that our current clinical trials struggle to enroll adequate numbers of minority men. Our inability to enroll a cross section of men that truly reflects the general population in prostate cancer clinical trials means that our results might not accurately reflect the best information for a minority man. The lack of [...]
Approximately 2 years ago Malecare and the New York State Prostate Coalition began asking questions about where the State of New York was hiding approximately $3,000,000 in funding for prostate cancer research. Each year New York State residents are asked to check off a little box on their state tax return donating an additional dollar [...]
